Kate M Lewis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/728189/publications.pdf

Version: 2024-02-01

		1162367	1473754
9	135	8	9
papers	citations	h-index	g-index
9	9	9	232
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Treatment with the NK1 Antagonist Emend Reduces Blood Brain Barrier Dysfunction and Edema Formation in an Experimental Model of Brain Tumors. PLoS ONE, 2014, 9, e97002.	1.1	21
2	Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood–brain barrier during extravasation and brain invasion. Clinical and Experimental Metastasis, 2013, 30, 1-12.	1.7	26
3	Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours. Cancer Cell International, 2013, 13, 5.	1.8	13
4	Asymmetric cell division: Implications for glioma development and treatment. Translational Neuroscience, 2013, 4, 484-503.	0.7	14
5	Blocking Neurogenic Inflammation for the Treatment of Acute Disorders of the Central Nervous System. International Journal of Inflammation, 2013, 2013, 1-16.	0.9	24
6	NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer. Anti-Cancer Drugs, 2013, 24, 344-354.	0.7	14
7	The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours. Recent Patents on CNS Drug Discovery, 2013, 8, 13-23.	0.9	7
8	Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours. Journal of Neuroimmunology, 2012, 250, 59-65.	1.1	8
9	Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface. Recent Patents on CNS Drug Discovery, 2011, 6, 31-40.	0.9	8